APS suppresses HCC by inhibiting OGT-mediated O-GlcNAcylation and promoting NLRP3+ M1-like TAMs enrichment, thereby enhancing anti-tumor immunity, highlighting APS as a potential immunomodulatory agent for HCC therapy.
Lv et al. (Tue,) studied this question.